Figure 6.

Patients achieving (a) pain freedom, (b) most bothersome symptom freedom, and (c) pain relief at 2 hours post-dose by migraine attack in patients who treated ≥ 5 attacks (ITT population).

ITT: intent-to-treat; MBS: most bothersome symptom.

Note: Pain freedom is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at 2 hours post-dose. MBS freedom is defined as the absence of the associated symptom of migraine (nausea, phonophobia, or photophobia) at 2 hours post-dose that was identified pre-dose as the MBS. Pain relief is defined as experiencing moderate or severe pain at baseline that becomes mild or none at 2 hours post-dose or mild pain at baseline that becomes none at 2 hours post-dose for each treated attack. Patients who recorded that no symptoms were present at baseline were excluded from the MBS analysis. Patients were assumed to not have achieved pain freedom at 2 hours if they did not have an associated pain severity rating at the 2-hour time point, took rescue medication within the first 2 hours, or used alternative medication prior to the study drug to treat the migraine attack.